Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GPR52 | Q9Y2T5 | 6/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27138365 | 0.85 | KDM4E (0.40) | L3MBTL1KDM4E | |
| SCHEMBL22440508 | 0.82 | — | — | |
| SCHEMBL3581100 | 0.78 | PARP1 (0.47) | PARP1L3MBTL1KDM4EPRKCQIRAK4 | |
| Hydrochloric Acid SCHEMBL3585465 | 0.77 | PARP1 (0.46) | PARP1L3MBTL1KDM4EPRKCQIRAK4 | |
| SCHEMBL27148684 | 0.76 | NUDT1 (0.46) | L3MBTL1KDM4E | |
| SCHEMBL21818593 | 0.75 | ACHE (0.40) | L3MBTL1KDM4E | |
| SCHEMBL14661353 | 0.75 | KDM4E (0.36) | PARP1L3MBTL1KDM4EPRKCQPI4K2A | |
| SCHEMBL30525181 | 0.75 | PARP1 (0.56) | PARP1L3MBTL1KDM4EGPR52PI4K2A | |
| SCHEMBL14661470 | 0.70 | KDM4E (0.37) | PARP1L3MBTL1KDM4EPRKCQPI4K2A | |
| SCHEMBL15882991 | 0.69 | ALDH1A1 (0.41) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2022115301-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | PARP1 2154/4885L3MBTL1 2040/4885KDM4E 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.